T-Cell Biomarker Predicts Which CLL Patients Will Respond to CAR … – Drug Discovery & Development
Drug Discovery & Development |
T-Cell Biomarker Predicts Which CLL Patients Will Respond to CAR …
Drug Discovery & Development Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don't respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients' immune systems are … Healthy T cells have a fighting chance for cell therapy | Penn Today |
